Abstract
Differentiation of post-therapeutic scar tissue from active lymphoma is unsatisfactory when using only morphological imaging approaches. Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) may provide superior clinical information by enabling biochemical tissue characterisation, with enhanced FDG uptake in viable post-therapeutic lymphoma masses and very low uptake in indolent fibrotic tissue. With this in mind, 15 recently published studies reporting the results of differentiation of viable lymphoma from scar tissue in 723 patients were analysed. Sensitivity of FDG-PET for detection of active disease was 71–100%, and the specificity was 69–100%. Accordingly, FDG-PET had a high negative predictive value of 80–100%. In contrast, the specificity and positive predictive value (PPV) of computed tomography were low (4–31% and 19–60%, respectively, except in one study in which the PPV was 82%). Residual masses that were positive on PET were associated with a progression-free survival of 0–40%. Although not perfect, the biochemical approach for characterisation of residual masses in lymphoma with FDG-PET at present seems the most accurate way to differentiate scar tissue from viable residual lymphoma.
Similar content being viewed by others
References
Dalla-Favera R, Gaidano GL. Lymphomas. In: De Vita VT, Rontrey SA, eds. Cancer, principles of oncology. Philadelphia: Lippincott Williams and Wilkins; 2001:2215–2387.
Aisenberg A. Problems in Hodgkin's disease management. Blood 1999; 93:761–779.
Reiser M, Diehl V. Current treatment of follicular non-Hodgkin's lymphoma. Eur J Cancer 2002; 38:1167–1172.
Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6:931–933.
Lowe V, Wiseman GA. Assessment of lymphoma therapy using18F-FDG PET. J Nucl Med 2002; 43:1028–1030.
Hoskin P. FDG PET in the management of lymphoma: a clinical perspective. Eur J Nucl Med 2002; 29:449–451.
Segall G. FDG PET imaging in patients with lymphoma: a clinical perspective. J Nucl Med 2001; 42:609–610.
DeWit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld D. Whole-body PET for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997; 8:57–60.
Cremerius U, Fabry U, Neuerburg J, Zinmy, Osieka R, Buell U. Positron emission tomography with18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998; 19:1055–1063.
Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999; 38:799–804.
Bangerter M, Moog F, Griesshammer M, et al. Role of whole-body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment. Radiography 1999; 5:155–163.
Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91:302–310.
Cremerius U, Fabry U, Kroll U, et al. Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen Lymphomen—Ergebnisse einer retrospektiven Studie an 72 Patienten. Nuklearmedizin 1999; 38:24–30.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429–433.
Maisey N, Hill M, Webb A, et al. Are18fluordeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000; 26:200–206.
Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85:613–618.
Spaepen K, Stroobants S, Dupont P, et al. Can positron emission tomography with (18F)-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 15:272–278.
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414–419.
Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793–800.
Weihrauch M, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using F-18-FDG for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98:2930–2934.
Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with (18F)2-fluoro-d-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002; 16:260–267.
De Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld D.18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12:29–37.
Hoekstra CJ, Paglianiti I, Hoekstra OS, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731–743.
Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S. Vortäuschung eines mediastinalen Non-Hodkin-Lymphomrezidivs durch diffuse Thymushyperplasie im18F-FDG-PET. Fortschr Röntgenstr 1996; 165:309–310.
Spaepen K, Mortelmans L. Evaluation of treatment response in patients with lymphoma using (18F)FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Q J Nucl Med 2001; 45:269–273.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reske, S.N. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S89–S96 (2003). https://doi.org/10.1007/s00259-003-1167-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-003-1167-4